This trial is a prospective, single-centre, randomized controlled, and non-inferiority study in which all men suspicious to have clinically significant prostate cancer. This study aims to determine whether a novel three-dimensional matrix positioning cognitive fusion targeted biopsy is non-inferior to software-based fusion targeted biopsy in the detection rate of clinically significant cancer in men without a prior biopsy.
This is a randomized controlled and non-inferiority trial in comparison of the novel three-dimensional matrix positioning cognitive fusion targeted biopsy between the software-based fusion targeted biopsy in the detection rate of clinically significant cancer in men without a prior biopsy.